Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine long-term extension in treatment-resistant major depressive disorder
NCT04829318Phase 4Completed
- Sponsor
- Janssen-Cilag
- Start
- Apr 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 4 trial of esketamine in major depressive disorder (MDD), sponsored by Janssen-Cilag. Started Apr 2021; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04829318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829318.